Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: Effect of hormonal treatment

Urologia Internationalis

Volumn 59, Issue 3, 1997, Pages 149-153

  Guate, José Luis ^a,b   Escaf, Safwan ^b   Menendez, Carmen Luz ^a   Del Valle, Miguel ^c   Vega, José Antonio ^c  

^a San Agustin Hospital   (Spain)

^b UNIVERSIDAD DE OVIEDO   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Benign prostatic hyperplasia; Chromogranin A; Hormonal therapy; Neuroendocrine cells; Prostate; Prostatic carcinoma

Indexed keywords

CHROMOGRANIN A;

ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

EID: 0030806629     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000283051     Document Type: Article

References (37)

1. Fujita T: Present status of paraneuron concept, Arch HistolCytol 1989:52(suppl): 1-8.
2. Kanno T: The physiology and cell biology of paraneurons, Arch Histol Cytol 1989;52 (suppl):9-12.
3. Di Sant’Agncse PA: Neuroendocrine differentiation in human prostatic carcinoma, Hum Pathol 1992:23:287-296.
4. Noordzij MA, Van Stccnbrugge GJ, Van dcr Kwast TH, Schroder EH: Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate, Urol Res 1995;22:333-341.
5. Huang ZY, Mcng FQ, Chen H: Relation between neuroendocrine expression of prostatic carcinoma and prognosis, Chung Hua I Hsuch TsaChih 1994;74:23-25,62-63.
6. Di Sant’Agncse PA, Cockctt ATK: Neuroendocrine differentiation in prostatic malignancy, Cancer 1996:78:357-361.
7. Azzopardi JG, Evans DJ: Argentaffin cells in prostatic carcinoma: Differentiation from lipo-fuscin and melanin in prostatic epithelium, J Pathol 1971:104:247-251.
8. Kazzaz BA: Argentaffin and argyrophil cells in the prostate, J Pathol 1974; 112:189-193.
9. Capclla C, Uscllini L, Buffa R, Frigerio B, Solcia E: The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumours, and non-tumour prostate: Histo-chemical and ultrastructural identification of the endocrine cells, Histopathology 1981;5: 175-192.
10. Aprikian AG, Cordon-Cardo C, Fair WR, Zhang Z, Bazinet M, Hamdy SM, Reuter VE: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma, J Urol 1994:151: 914-919.
11. Stratton M, Evans DJ, Lampert IA: Prostatic adenocarcinoma evolving into carcinoid: Selective effect of hormonal treatment, J Clin Pathol 1986:39:750-756.
12. Turbat-Hcrrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM: Neuroendocrine differentiation in prostatic carcinomas: A retrospective autopsy study, Arch Pathol Lab Med 1988:112:1100-1105.
13. Dauge MC, Delmas V: APUD type endocrine tumour of the prostate: Incidence and prognosis in association with adenocarcinoma: in Murphy GP, Khoury S, Kliiss R, Chatclain C, Denis L (eds): Prostate Cancer, A, Research, Endocrine Treatment, and Histopathology, New York, I.iss, 1987, pp 529-531.
14. Van Haaften-Day C, Raghavan D, Russel P, Wills EJ, Gregory P, Tilley W, Horsfall DJ: Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma, Prostate 1987; 11:271-279.
15. Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, Grimelius L: Peptide-hormonc-and serotonin-immunorcactive tumor cells in carcinoma of the prostate, Pathol Res Pract 1987;182:298-307.
16. Cohen RJ, Glczerson G, Haffcjcc Z, Afrika D: Prostatic carcinoma: Histological and immu-nohistological factors affecting prognosis, Br J Urol 1990:66:405-410.
17. Cohen RJ, Glczerson G, Haffejee Z: Neuroendocrine cells: A new prognostic parameter in prostate cancer, Br J Urol 1991:68:258-262.
18. Bohrer MH, Schmoll J: Immunhistochemischc und morphometrische Untersuchungen zur neuroendokrinen Differenzierung in Prostatakarzinomen, Verli Dtsch Ges Pathol 1993;77P: 107-110.
19. Nakada SY, Di Sant Agnesc PA, Moynes RA, Hiipakka RA, Liao S, Cockctt ATK, Abrahamsson P: The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue, Cancer Res 1993:53: 1967-1970.
20. Cohen R, Glczerson G, Taylor L, Grundle H, Naude J: The neuroendocrine cell population of the human prostate gland, J Urol 1993:150: 365-368.
21. Abrahamsson PA, Falkmer S, Falt K, Grimelius L: The course of neuroendocrine differentiation in prostatic carcinomas: An immunohis-tochemical study testing chromogranin A as an ‘endocrine marker’, Pathol Res Pract 1989; 185:373-380.
22. Kadmon D, Thomson TC, Lynch GR, Scardino PT: Elevated plasma chromogranin A concentrations in prostatic carcinoma, J Urol 1991:146:358-361.
23. Fctissof F, Dubois MP, Arbcille-Brassart B, Lanson Y, Boivin F, Jobard P: Endocrine cells in the prostate gland, urothelium, and Brenner tumours, Immunohistological and ultrastructural studies, Virchows Arch B Cell Pathol 1983:42:53-64.
24. Garcia-Suarez O, Naves FJ, Del Valle ME, Esteban I, Bronzetti E, Vazquez E, Vega JA: Distribution of p75 and trk-neurotrophin receptor proteins in adult human sympathetic ganglia, Anat Embrvol (Berl) 1996; 193:577-583.
25. 2+-dependent manner, Trends Neurosci 1995:18:177-183.
26. Vittoria A, La Mura C, Cocca T, Cecio OA: Serotonin, somatostatin and chromogranin A containing cells of the urethroprostatic complex in the sheep: An immunocytochcmical and immunofluoresccnt study, J Anat 1990: 171:169-178.
27. Di Sant’Agnesc PA, De Mcsy Jensen KL, Chu-rukian CJ, Agarwal MM: Human proslatic en-docrine-paracrine (APUD) cells: Distributional analysis with a comparison of serotonin and neuron specific cnolase immunoreactivity and silver stains, Arch Pathol Lab Med 1985:109: 607-612.
28. Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, Grimelius L: Peptide-hormonc-and serotonin-immunorcactive cells in normal and hyperplastic prostate glands, Pathol Res Pract 1986:181:675-683.
29. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatie adenocarcinoma, Cancer 1993; 71:3952-3965.
30. Pollice L, Rcsta L, Simone G: APUD cells in normal and hyperplastic prostates, Ric Clin Lab 1979;9:273-278.
31. Cockett AT, Di Sant’Agnesc PA, Gopinath P, Schoen SR, Abrahamsson PA: Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia, Urology 1993; 42:512-519.
32. Van de Voorde WM, Van Poppcl HP, Verbck-en F.K, Oven RH: Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate, Mod Pathol 1995:8:591-598.
33. Di Sant’Agnesc PA: Neuroendocrine differentiation in prostatic adenocarcinoma does not represent true Paneth cell differentiation, Hum Pathol 1994;25:115-116.
34. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, Meria P, Teil-lac P, Fiet J, Le Due A: Plasma neuroendocrine markers in patients with benign hyperplasia and prostatic carcinoma, J Urol 1996:155: 1340-1343.
35. Bonkhoff H, Rembergcr SK: Androgen receptor status in endocrine paracrine cell types of the normal, hyperplastic, and neoplastic human prostate, Virchows Arch A Pathol Anat Histopathol 1993;423:291-294.
36. Krijnen JLM, Janssen PJA, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, van der Kwast TH: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993;100:393-398.
37. Di Sant’Agnese PA, Dc Mcsy Jensen KL: Neuroendocrine differentiation in prostatic carcinoma, Hum Pathol 1987;18:849-856.